A Phase II Study to Evaluate the Safety and Efficacy of anti-CD6 monoclonal antibody (T1h mAb) in Patients with Active Psoriasis.
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2016
At a glance
- Drugs Itolizumab (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biocon
- 03 Feb 2010 Status changed from active, no longer recruiting to completed Clinical Trials Registry - India.
- 16 Oct 2009 New trial record.